1DeVane C L. Pharmacokinetics, drug interactions, and tolerability of valproate [J ] Psychopharrnacol Bull, 2003, 37( Suppl 2) :25-42.
2Buchwald M, Kramer O H, Heinzel T. HDACi-targets beyond chromatin[J]. Cancer Lett, 2009, 280(2:160- 167.
3Condorelli F, Gnemmi I, Vallario A. Inhibitors of histone deacetylase (HDAC) restore the p53 pathway in neuro- blastoma cells[J]. Br J Pharmacol, 2008, 153 (4) :657- 668.
4Garcia-Manero G, Issa J P. Histone deacetylase inhibi- tors: a review of their clinical status as antineoplasticagents[J]. Cancer Invest, 2005, 23 (7) :635-642.
5Atadja P W. HDAC inhibitors and cancer therapy [ J ]. Prog Drug Res, 2011, 67 : 175-195.
6Chen X, Wong P, Radany E. HDAC inhibitor, valproic acid, induces p53-dependent radiosensitization of colon cancer cells [J ]. Cancer Biother Radiopharm, 2009, 24 (6) :689-699.
7Norden A D, Drappatz J, Wen P Y. Novel anti-angiogen- ic therapies for malignant gliomas [J ]. Lancet Neurol, 2008, 7(12) :1152-1160.
8Niyazi M, Siefert A, Schwarz S B, et al. Therapeutic op- tions for recurrent malignant glioma [J ]. Radiother On- col, 2011, 98(1):1-14.
9Frew A J, Johnstone R W, Bolden J E. Enhancing the apoptotic and therapeutic effects of HDAC inhibitors [J ] Cancer Lett, 2009, 280(2):125-133.
10Koprinarova M, Botev P, Russev G. Histone deacety- lase inhibitor sodium butyrate enhances cellular radiosen- sitivity by inhibiting both DNA nonbomologous end join- ing and homologous recombination [J ]. DNA Repair (Amst), 2011, 10(9) :970-977.
